Vera Therapeutics, Inc. (VERA)
| Market Cap | 2.28B +17.5% |
| Revenue (ttm) | n/a |
| Net Income | -401.90M |
| EPS | -5.89 |
| Shares Out | 72.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,421 |
| Open | 31.32 |
| Previous Close | 30.94 |
| Day's Range | 31.13 - 31.91 |
| 52-Week Range | 23.05 - 56.05 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 74.20 (+134.44%) |
| Earnings Date | Nov 5, 2026 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $74.2, which is an increase of 134.44% from the latest price.
News
Vera Therapeutics Transcript: Study update
ORIGIN 3 showed atacicept reduced eGFR loss to less than 1 mL/min/year and lowered composite kidney progression risk by 76% through week 104 in high-risk IgA nephropathy. A supplemental BLA was planned for the quarter, with full FDA approval anticipated in mid-2027.
Vera Therapeutics Press release: Study update
Vera Therapeutics issued a press release on October 22, 2026, disclosing material business information to investors.
Vera Therapeutics Slides: Study update
Vera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 22, 2026.
Vera Therapeutics announces publication of ORIGIN 3 final efficacy analysis
Vera Therapeutics (VERA) announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy at risk for disease progression was presented as…
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk ...
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary sessi...
Vera Therapeutics initiated with a Market Perform at Leerink
Leerink initiated coverage of Vera Therapeutics (VERA) with a Market Perform rating and $34 price target The firm thinks Trutakna can launch “reasonably well in the near term,” but argues…
Vera Therapeutics price target lowered to $60 from $66 at BofA
BofA lowered the firm’s price target on Vera Therapeutics (VERA) to $60 from $66 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview…
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensati...
Vera Therapeutics announces ORIGIN 3 final efficacy analysis of Trutakna
Vera Therapeutics (VERA) announced that there will be multiple presentations at the American Society of Nephrology, ASN, Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final…
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026
Vera Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Final phase III data showed TRUTAKNA significantly slowed kidney function decline and reduced risk of hard outcomes in IgAN, supporting a strong U.S. launch with over 350 patient starts in 10 weeks. The company is expanding globally, pursuing new indications, and maintains a robust financial position.
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
Why is Vera Therapeutics stock reversing its premarket gains?
Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (...
Vera Therapeutics ORIGIN 3 study results positive, says Raymond James
After Vera Therapeutics (VERA) reported the final efficacy analysis for their pivotal ORIGIN 3 study needed for full approval of Trutakna in IgAN, Raymond James analyst Ryan Deschner called the…
Morning Movers: Vera Therapeutics surges after reporting IgAN study data
Stock futures are pointing to another lower open as investors brace for the Federal Reserve to begin its two-day policy meeting, with the central bank widely expected to raise interest…
Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data
07:05 EDT Vera Therapeutics (VERA) up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data
Vera Therapeutics’ trutakna meets all efficacy endpoints in IgAN trial
Vera Therapeutics (VERA) announced that trutakna met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy, or IgAN, at risk…
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progression Through 2 Years in ORIGIN 3 Final Analysis
Vera Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Trutakna achieved accelerated approval and commercial launch, demonstrating strong efficacy in IgA nephropathy with a favorable safety profile and broad label. Early launch metrics are positive, with robust payer support and a well-prepared sales force targeting a large market.
Vera Therapeutics price target raised to $83 from $76 at JPMorgan
JPMorgan raised the firm’s price target on Vera Therapeutics (VERA) to $83 from $76 and keeps an Overweight rating on the shares. The firm updated the company’s model ahead of…
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present a...
3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts
Analysts see strong momentum in some stocks this week, including Fervo Energy ($FRVO), Vera Therapeutics ($VERA), and Hut 8 ($HUT). While each stock carries risk, analysts believe all three have more…
Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vera Therapeutics (VERA) to $90 from $125 and keeps a Buy rating on the shares. The firm reduced peak revenue projections for…
Vera Therapeutics price target raised to $84 from $78 at Raymond James
Raymond James analyst Ryan Deschner raised the firm’s price target on Vera Therapeutics (VERA) to $84 from $78 and keeps a Strong Buy rating on the shares. Vera’s Trutakna launch…